



Clinical results for Episealer® accepted as poster presentation for the ESSKA Congress

Episurf Medical (Nasdaq: EPIS B) today announces that a scientific abstract presenting clinical results from the use of the Episealer® implant has been accepted as a poster presentation for the upcoming ESSKA Congress in Milan. The abstract, "*Clinical 2 years results after implantation of patient specific mini-metal implants for (osteo-)chondral knee lesions in middle-aged patients after previous frustrane cartilage surgery*", is authored by Priv.-Doz. Dr. med. Clemens Kösters from the Maria-Josef-Hospital Greven in Germany.

ESSKA (European Society for Sports Traumatology, Knee Surgery and Arthroscopy) is a European organization focusing on degenerative joint diseases and sports medicine. The ESSKA Congress is held every second year, and the next meeting will take place in Milan on May 6-9, 2020.

"The ESSKA Congress is an important congress, and we are pleased that a scientific abstract with clinical results from the use of Episealer® has been accepted as a poster presentation. As we have said before, we are experiencing an increasing interest in our technology. This is yet another proof of that. Commercial break-throughs in our industry must start from the science; hence, this is a very important period for us," says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel: +46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's *uiFidelity®* system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.